RE:RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustionNovartis’ anti-TIM-3 antibody (MBG453/sabatolimab) failed to simultaneously activate the immune system and suppress the proliferation of cancer cells.
The TIM-3 canadidate was intended to be combined with an immune checkpoint inhibitor.
Roche removed their PD-1xTIM-3 bispecific from its pipeline in 2022